Medical tests on children living in three towns near the crippled Fukushima Dai-Ichi nuclear plant found 45 percent of those surveyed suffered low-level thyroid radiation exposure, Japan’s government said in a statement.
Pluristem Therapeutics Inc., a developer of placenta-based stem-cell therapies, will work with a U.S. National Institutes of Health unit to evaluate the company’s PLX cells for the treatment of radiation exposure.
Low levels of radiation exposure probably will become “a fact of life” for U.S. military forces flying relief and rescue missions to aid victims of Japan’s earthquake as they near areas affected by leaks from a damaged nuclear plant, according to a U.S. Navy spokesman.
Tension at U.S. airports between security and privacy may peak Nov. 24, one of the year’s busiest travel days, with a protest over growing use of full-body X-rays and of extensive pat-downs for those who reject the scans.
Radiation from the Fukushima nuclear plant may cause as many as 1,300 cancer deaths globally, according to a study that showed fallout from Tokyo Electric Power Co.’s crippled reactors may be deadlier than predicted.